Actively Recruiting
Phase 2 Study of Oral JMKX003142 for Treating Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease ADPKD in Adults Aged 18 to 55
Led by Jemincare · Updated on 2025-07-03
135
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of a drug called JMKX003142 in adults aged 18 to 55 with rapidly progressive autosomal dominant polycystic kidney disease ADPKD. This Phase 2, multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the drugs efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics. The study focuses on how the drug impacts kidney volume changes and kidney function in patients with this condition. Participants will be randomly assigned to receive either oral JMKX003142 or a matching placebo. The study is designed to compare these two groups over a 52-week period. The trial includes careful monitoring of participants health and response to the drug, with a focus on kidney size and function as primary and secondary outcomes. Throughout the study, participants will undergo assessments including measurements of total kidney volume TKV and estimated glomerular filtration rate eGFR. These assessments occur at the start and during the 52 weeks of treatment to monitor changes. Participants will also be evaluated for safety and tolerability of the drug, with adherence and health status tracked regularly until the study ends in 2027.
CONDITIONS
Brief Title
Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Research Team
X
xiaojun zhou
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here